BioSpace News Archive

DaVita Inc. announced the pricing of its previously announced private offering of $1.75 billion aggregate principal amount of senior notes due 2030.

LAIX Inc. (“LAIX” or the “Company”) (NYSE: LAIX), an artificial intelligence (AI) company in China that creates and delivers products and services to popularize English learning, today announced its unaudited financial results for the first quarter ended March 31, 2020.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on Tuesday 2 June 2020 at 7.30am, Australia Eastern Standard Time (AEST) / Monday 1 June 2020 at 5.30pm, Eastern Daylight Time (EDT).

Fortress Biotech, Inc., an innovative biopharmaceutical company, announced that it has priced an underwritten public offering of 555,556 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $18.00 per share, with expected gross proceeds to Fortress of approximately $10 million.

Today, the U.S. Food and Drug Administration approved artesunate for injection to treat severe malaria in adult and pediatric patients. Treatment of severe malaria with intravenous (IV) artesunate should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.

Los Angeles Surgeon Gabriel Goren, MD says ‘Rejuvahands TM’ is the ONLY enduring option for seniority associated unsightly looking bulging hand vein

Shuwen Biotech Co. Ltd., a China-based leader in innovative diagnostics announced today the peer-reviewed publication of data highlighting the potential of its breakthrough point-of-care test in rapidly diagnosing Preeclampsia among women who are admitted to the hospital. The paper, entitled “Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins”, w

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual 2020 Healthcare Conference on Tuesday, June 2, 2020, at 1:00 p.m. ET.

Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will present a company overview at the upcoming Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020 at 3:30 p.m. ET.

Daxor Corporation, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, announced that its CEO, Michael Feldschuh, will be a panelist in Maxim Group and M-Vest’s COVID-19 Virtual Series on May 27, 2020.